PRRT2 and asthma: To obtain complete immunosuppressive effects, the inhibition of more than PKCθ appears to be needed, and the pharmacologic inhibition of multiple PKC isotypes may provide a successful approach to avert T cell effector functions that are relevant for diseases such as psoriasis, atopic dermatitis, and allergies, as well as other indications, including asthma, rheumatoid arthritis, multiple sclerosis, and transplant rejections.